PolarCool (POLAR) Q3 2024 earnings summary

Executive summary

• Achieved 74% year-over-year net sales growth in Q3 2024, driven by new and extended contracts in sports medicine markets.

• Submitted De Novo application to the US FDA, preparing for US market launch with an employee already stationed in the US.

• Signed distributor agreement in Australia following regulatory approval, targeting significant expansion in rugby and contact sports.

• Continued expansion in European sports, securing new and extended agreements with major hockey, rugby, handball, and boxing organizations.

• Developed an aggressive business and marketing plan for 2025, aiming for profitability as recurring revenue base grows.

Financial highlights

• Net sales for Q3 2024 reached SEK 566k, up from SEK 325k in Q3 2023, a 74% increase year-over-year.

• Operating loss for Q3 2024 was SEK -2,907k, impacted by SEK 746k in one-time FDA application costs.

• Cash and cash equivalents at period end were SEK 9,979k, up from SEK 658k a year earlier.

• Equity at period end was SEK 15,437k, with a solid equity ratio of 87%.

• Result per share for Q3 2024 was SEK 0.00, compared to SEK 0.11 in Q3 2023.

Outlook and guidance

• Focus remains on scaling up sales in Europe and establishing presence in Australia and South Africa.

• Full-scale US launch planned for 2025–2026, pending FDA approval; short-term goal is profitability in 2025.

• Cost base expected to decrease, with 150 leased systems projected to cover current operating expenses.